[Artículo traducido] Perfil de seguridad a largo plazo y usos fuera de indicación de los inhibidores de JAK en dermatología

Sweeney, 2007, Primer: signal transduction in rheumatic disease – a clinician's guide, Nat Clin Pract Rheumatol., 3, 651, 10.1038/ncprheum0631 Goll, 2018, New-generation JAK inhibitors: how selective can they be?, Lancet., 391, 2477, 10.1016/S0140-6736(18)31325-4 Solimani, 2019, Emerging topical and systemic JAK inhibitors in dermatology, Front Immunol., 10, 2847, 10.3389/fimmu.2019.02847 Hoisnard, 2022, Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database, Sci Rep., 12, 7140, 10.1038/s41598-022-10777-w Shreberk-Hassidim, 2017, Janus kinase inhibitors in dermatology: a systematic review, J Am Acad Dermatol., 76, 745, 10.1016/j.jaad.2016.12.004 Daniele, 2022, JAK inhibitor safety compared to traditional systemic immunosuppressive therapies, J Drugs Dermatol., 21, 1298, 10.36849/JDD.7187 Yates, 2021, Venous thromboembolism risk with JAK inhibitors: a meta-analysis, Arthritis Rheumatol., 73, 779, 10.1002/art.41580 Chen, 2022, Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with Janus kinase inhibitors: a systematic review and meta-analysis, JAMA Dermatol., 158, 1254, 10.1001/jamadermatol.2022.3516 Elmariah, 2022, JAK in the [black] box: a dermatology perspective on systemic JAK inhibitor safety, Am J Clin Dermatol., 23, 427, 10.1007/s40257-022-00701-3 Simpson, 2021, Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program, Am J Clin Dermatol., 22, 693, 10.1007/s40257-021-00618-3 Eichenfield, 2021, Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial, JAMA Dermatol., 157, 1165, 10.1001/jamadermatol.2021.2830 Drucker, 2022, Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis, JAMA Dermatol., 158, 523, 10.1001/jamadermatol.2022.0455 Wojciechowski, 2022, Population pharmacokinetic–pharmacodynamic modelling of platelet time-courses following administration of abrocitinib, Br J Clin Pharmacol., 88, 3856, 10.1111/bcp.15334 Bieber, 2022, A review of safety outcomes from clinical trials of baricitinib in rheumatology, dermatology and COVID-19, Adv Ther., 39, 4910, 10.1007/s12325-022-02281-4 Bieber, 2021, Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials, J Eur Acad Dermatol Venereol., 35, 476, 10.1111/jdv.16948 King, 2021, Extended safety analysis of baricitinib 2 mg in adult patients with atopic dermatitis: an integrated analysis from eight randomized clinical trials, Am J Clin Dermatol., 22, 395, 10.1007/s40257-021-00602-x King, 2023, Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials, Br J Dermatol., 188, 218, 10.1093/bjd/ljac059 Papp, 2016, A randomized phase 2 b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis, Br J Dermatol., 174, 1266, 10.1111/bjd.14403 Guttman-Yassky, 2021, Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials, Lancet., 397, 2151, 10.1016/S0140-6736(21)00588-2 Blauvelt, 2021, Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial, JAMA Dermatol., 157, 1047, 10.1001/jamadermatol.2021.3023 Reich, 2021, Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet., 397, 2169, 10.1016/S0140-6736(21)00589-4 Guttman-Yassky, 2020, Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial, J Allergy Clin Immunol., 145, 877, 10.1016/j.jaci.2019.11.025 Harkins, 2023, Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta-analysis, Int J Rheum Dis., 26, 31, 10.1111/1756-185X.14447 Burmester, 2023, Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis, RMD Open., 9, e002735, 10.1136/rmdopen-2022-002735 Hosking, 2018, Topical Janus kinase inhibitors: a review of applications in dermatology, J Am Acad Dermatol., 79, 535, 10.1016/j.jaad.2018.04.018 Olsen, 2020, Ruxolitinib cream for the treatment of patients with alopecia areata: a 2-part, double-blind, randomized, vehicle-controlled phase 2 study, J Am Acad Dermatol., 82, 412, 10.1016/j.jaad.2019.10.016 Słuczanowska-Głąbowska, 2021, Role of Janus kinase inhibitors in therapy of psoriasis, J Clin Med., 10, 4307, 10.3390/jcm10194307 Kim, 2020, Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream, J Allergy Clin Immunol., 145, 572, 10.1016/j.jaci.2019.08.042 Papp, 2021, Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies, J Am Acad Dermatol., 85, 863, 10.1016/j.jaad.2021.04.085 Zhao, 2022, A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib, JAAD Case Rep., 22, 99, 10.1016/j.jdcr.2022.02.027 Baltazar, 2022, Occupational airborne allergic contact dermatitis to invasive compositae species treated with abrocitinib: a reporte de caso, Contact Dermat., 87, 542, 10.1111/cod.14204 Gómez-Arias, 2021, Efficacy and safety of Janus kinase inhibitors in type I interferon-mediated monogenic autoinflammatory disorders: a scoping review, Dermatol Ther (Heidelb)., 11, 733, 10.1007/s13555-021-00517-9 Álvarez-Reguera, 2022, Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: reporte de caso and literature review, Ther Adv Musculoskelet Dis., 14, 10.1177/1759720X221093211 Boyadzhieva, 2022, Effectiveness and safety of JAK inhibitors in autoinflammatory diseases: a systematic review, Front Med (Lausanne)., 9, 930071, 10.3389/fmed.2022.930071 Heiblig, 2022, Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study, Blood., 140, 927, 10.1182/blood.2022016642 Ladhari, 2019, Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy, Rheumatology (Oxford)., 58, 736, 10.1093/rheumatology/key414 Zimmermann, 2019, Assessment of clinical response to Janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation, JAMA Dermatol., 155, 342, 10.1001/jamadermatol.2018.5077 Kreuter, 2022, Baricitinib for recalcitrant subacute cutaneous lupus erythematosus with concomitant frontal fibrosing alopecia, Clin Exp Dermatol., 47, 787, 10.1111/ced.15044 Maeshima, 2020, Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus, Ann Rheum Dis., 79, 674, 10.1136/annrheumdis-2019-216571 Joos, 2022, Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib, Clin Exp Dermatol., 47, 748, 10.1111/ced.15005 Fornaro, 2019, Efficacy of baricitinib on refractory skin papulosquamous rash in a patient with systemic lupus erythematosus, Rheumatology (Oxford)., 59, 1792, 10.1093/rheumatology/kez561 Holtzman, 2020, Efficacy and safety of baricitinib in refractory chronic graft-versus-host disease (cGVHD): preliminary analysis results of a phase 1/2 study, Blood., 136, 1, 10.1182/blood-2020-140392 Rosenberg, 2022, Baricitinib treatment of severe chronic hand eczema: two reporte de casos, Contact Dermat., 86, 419, 10.1111/cod.14039 He, 2021, Effectiveness of baricitinib in prurigo-type atopic dermatitis: a reporte de caso, Dermatol Ther., 34, e14878, 10.1111/dth.14878 Pereira, 2022, Improvement of chronic nodular prurigo with baricitinib, J Eur Acad Dermatol Venereol., 36, e486, 10.1111/jdv.17991 Yin, 2022, Successful treatment of refractory prurigo nodularis with baricitinib, Dermatol Therapy., 35, e15642, 10.1111/dth.15642 Zhao, 2022, Baricitinib for the treatment of cutaneous dermatomyositis: a prospective, open-label study, J Am Acad Dermatol., 87, 1374, 10.1016/j.jaad.2022.08.025 Fischer, 2022, Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib, Br J Dermatol., 187, 432, 10.1111/bjd.21252 Delvino, 2020, Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis, Rheumatology (Oxford)., 59, 4003, 10.1093/rheumatology/keaa377 Sehgal, 2021, Successful treatment with baricitinib in a patient with refractory eosinophilic fasciitis, J Rheumatol., 48, 948, 10.3899/jrheum.200998 Moussa, 2022, Treatment of lichen planopilaris with baricitinib: a retrospective study, J Am Acad Dermatol., 87, 663, 10.1016/j.jaad.2022.02.027 Damsky, 2020, Jak inhibition prevents bleomycin-induced fibrosis in mice and is effective in patients with morphea, J Invest Dermatol., 140, 1446, 10.1016/j.jid.2019.12.019 Kim, 2023, Rapid improvement of refractory generalized granuloma annulare with the Janus kinase inhibitor baricitinib in two patients, Clin Exp Dermatol., 48, 375, 10.1093/ced/llac110 Ballová, 2022, Recalcitrant granuloma annulare induced by two different biologic agents resolved after Janus kinase inhibitor treatment, Dermatol Ther., 35, e15641, 10.1111/dth.15641 Yan, 2022, Successful treatment of generalized granuloma annulare with baricitinib, J Eur Acad Dermatol Venereol., 36, e500, 10.1111/jdv.18031 Šteňová, 2020, Hypereosinophilic syndrome – a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy, Clin Rheumatol., 39, 3507, 10.1007/s10067-020-05134-z Kalantari, 2022, A literature review on Janus kinase (JAK) inhibitors for the treatment of immunobullous disorders, Int Immunopharmacol., 110, 108923, 10.1016/j.intimp.2022.108923 Xiao, 2022, Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib, Dermatol Ther., 35, e15754, 10.1111/dth.15754 Moussa, 2022, Effective treatment of refractory lichen planus pemphigoides with a Janus kinase-1/2 inhibitor, Clin Exp Dermatol., 47, 2040, 10.1111/ced.15344 Kim, 2021, Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis, Ann Rheum Dis., 80, 406, 10.1136/annrheumdis-2020-218690 Wang, 2022, The efficacy of baricitinib in real-world patients with refractory or severe juvenile dermatomyositis: a monocentric retrospective study, Research Square. Le Voyer, 2021, JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study, Rheumatology (Oxford)., 60, 5801, 10.1093/rheumatology/keab116 Papadopoulou, 2019, Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis, Brain., 142, e8, 10.1093/brain/awz005 Agud-Dios, 2022, Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy, Dermatol Ther., 35, e15960, 10.1111/dth.15960 Pünchera, 2022, Treatment of severe nail lichen planus with baricitinib, JAMA Dermatol., 158, 107, 10.1001/jamadermatol.2021.5082 Han, 2022, Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy, Front Immunol., 13, 1008392, 10.3389/fimmu.2022.1008392 Zhang, 2022, Refractory livedoid vasculopathy in a child successfully treated with baricitinib, Dermatol Ther., 35, e15659, 10.1111/dth.15659 Xiao, 2022, Refractory livedoid vasculopathy successfully treated with baricitinib, Int J Dermatol. Zhang, 2022, The efficacy and safety of tofacitinib, peficitinib, solcitinib, baricitinib, abrocitinib and deucravacitinib in plaque psoriasis – a network meta-analysis, J Eur Acad Dermatol Venereol., 36, 1937, 10.1111/jdv.18263 Han, 2021, Inhibition of progression of acrodermatitis continua of hallopeau with baricitinib, JAMA Dermatol., 157, 466, 10.1001/jamadermatol.2021.0045 Scheinberg, 2021, Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor, J Transl Autoimmun., 4, 100099, 10.1016/j.jtauto.2021.100099 Nousari, 2021, Successful use of baricitinib in the treatment of refractory rheumatoid arthritis-associated Sweet syndrome, Clin Exp Dermatol., 46, 1330, 10.1111/ced.14712 Hou, 2022, JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis, Front Med (Lausanne)., 9, 859330, 10.3389/fmed.2022.859330 Fujita, 2019, Case Rep Rheumatol., 2019, 5293981 Boleto, 2021, Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis-rheumatoid arthritis overlap syndrome, Clin Exp Rheumatol., 39, 163, 10.55563/clinexprheumatol/gu1ac8 Moriana, 2022, JAK inhibitors and systemic sclerosis: A systematic review of the literature, Autoimmun Rev., 21, 103168, 10.1016/j.autrev.2022.103168 Mumford, 2020, Repigmentation of vitiligo with oral baricitinib, Australas J Dermatol., 61, 374, 10.1111/ajd.13348 Cantelli, 2022, Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report, Dermatol Ther., 35, e15346, 10.1111/dth.15346 Bourkas, 2022, Upadacitinib for the treatment of alopecia areata and severe atopic dermatitis in a paediatric patient: A case report, SAGE Open Med Case Rep., 10 Asfour, 2022, Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib, Int J Dermatol., 61, e416, 10.1111/ijd.16316 Youssef, 2023, Effective treatment of alopecia universalis with oral upadacitinib, JAAD Case Rep., 31, 80, 10.1016/j.jdcr.2022.08.014 Balestri, 2022, Treatment of Oral Erosive Lichen Planus With Upadacitinib, JAMA Dermatol., 158, 457, 10.1001/jamadermatol.2022.0147 Motamed-Sanaye, 2022, JAK inhibitors in lichen planus: a review of pathogenesis and treatments, J Dermatol Treat., 33, 3098, 10.1080/09546634.2022.2116926 Murphy, 2021, Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis, JAMA Dermatol., 157, 1477, 10.1001/jamadermatol.2021.4084 Sondermann, 2022, Successful therapy of disseminated patch-type granuloma annulare with upadacitinib in a patient with rheumatoid arthritis, Dermatol Ther-, 35, e15211, 10.1111/dth.15211 AbbVie. A phase 2, multicenter, randomized, placebo-controlled, double-blind study to evaluate upadacitinib in adult subjects with moderate to severe hidradenitis suppurativa. clinicaltrials.gov; 2023. [Internet], [consultado 29 Mar 2023]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT04430855 Bokhari, 2018, Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study, Int J Dermatol., 57, 1464, 10.1111/ijd.14192 Bayart, 2017, Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata, J Am Acad Dermatol., 77, 167, 10.1016/j.jaad.2017.03.024 Gordon, 2019, Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata, J Eur Acad Dermatol Venereol., 33, e156, 10.1111/jdv.15383 Craiglow, 2016, Topical Ruxolitinib for the Treatment of Alopecia Universalis, JAMA Dermatol., 152, 490, 10.1001/jamadermatol.2015.4445 Deeb, 2017, A case of Topical Ruxolitinib Treatment Failure in Alopecia Areata, J Cutan Med Surg., 21, 562, 10.1177/1203475417716363 Cowen E, Phase II study of topical ruxolitinib for cutaneous chronic graft versus host disease (CGVHD). clinicaltrials.gov; 2022. [Internet], [consultado 29 Mar 2023]. Disponible en: https://clinicaltrials.gov/ct2/show/study/NCT03395340 Park, 2022, Treatment of cutaneous lupus with topical ruxolitinib cream, JAAD Case Rep., 28, 133, 10.1016/j.jdcr.2022.08.038 Brumfiel, 2022, Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study, J Invest Dermatol., 142, 2109, 10.1016/j.jid.2022.01.015 Nugent, 2022, Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream, JAAD Case Rep., 29, 25, 10.1016/j.jdcr.2022.08.028 Punwani, 2012, Preliminary clinical activity of a topical JAK1/2 inhibitor in the treatment of psoriasis, J Am Acad Dermatol., 67, 658, 10.1016/j.jaad.2011.12.018 Punwani, 2015, Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor, Br J Dermatol., 173, 989, 10.1111/bjd.13994 Incyte Corporation. A double-blind, randomized, vehicle-controlled dose ranging study of the effect of INCB018424 phosphate cream when applied to patients with plaque psoriasis. clinicaltrials.gov; 2022. [Internet], [consultado 29 Mar 2023]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT00778700 Incyte Corporation. An open label, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and preliminary efficacy study of ruxolitinib when applied to patients with plaque psoriasis involving 2–20% body surface area (BSA). clinicaltrials.gov; 2022. [Internet], [consultado 29 Mar 2023]. Disponible en: https://clinicaltrials.gov/ct2/show/NCT00617994 Pope, 2022, Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis, JAAD Case Rep., 24, 59, 10.1016/j.jdcr.2022.04.003 Nash, 2021, Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement, Ann Rheum Dis., 80, 71, 10.1136/annrheumdis-2020-218398 EMA. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. European Medicines Agency. [Internet], [consultado 30 Mar 2023]. Disponible en: https://www.ema.europa.eu/en/news/ema-confirms-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic Waldman, 2023, Herpes zoster subunit vaccine for patients initiating a Janus kinase inhibitor, J Am Acad Dermatol., 88, 697, 10.1016/j.jaad.2022.08.040 Werner, 2022, Impact of off-label use regulations on patient care in dermatology – a prospective study of cost-coverage applications filed by tertiary dermatology clinics throughout Germany, J Eur Acad Dermatol Venereol., 36, 2241, 10.1111/jdv.18357